The systemic safety of bromfenac ophthalmic solution 0.09%.

Study Objective: The aim of this study was to evaluate the systemic safety of a commercially available bromfenac ophthalmic solution 0.09% for the treatment of postoperative inflammation and reduction of ocular pain in subjects who have undergone cataract extraction.

Design: Two phase III, multicenter, randomized, double-masked, parallel, placebo-controlled, clinical trials were conducted under a common protocol.

Long-term results with the White glaucoma pump-shunt.

A White glaucoma pump-shunt was inserted in 16 eyes in 15 patients, 2 to 76 years of age (10 female and 5 male patients; 6 were white, 6 were black, and 3 were Hispanic). Six had primary open-angle glaucoma, 2 glaucoma in aphakia, 1 congenital glaucoma, 4 secondary glaucoma, 2 neovascular glaucoma, and 1 glaucoma in pseudophakia. There were no complete successes.